Why LB Pharmaceuticals Inc’s (LBRX) Stock Is Down 5.52%
As of Monday, October 12, LB Pharmaceuticals Inc’s LBRX share price has dipped by 5.52%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Commentary & Analysis
Why LB Pharmaceuticals Inc’s (LBRX) Stock Is Up 6.82%
As of Friday, October 09, LB Pharmaceuticals Inc’s LBRX share price has surged by 6.82%, which has investors questioning if this is right time to sell.Michael Rose
Why LB Pharmaceuticals Inc’s (LBRX) Stock Is Down 5.55%
As of Wednesday, September 23, LB Pharmaceuticals Inc’s LBRX share price has dipped by 5.55%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why LB Pharmaceuticals Inc’s (LBRX) Stock Is Up 5.36%
As of Tuesday, August 04, LB Pharmaceuticals Inc’s LBRX share price has surged by 5.36%, which has investors questioning if this is right time to sell.Jenna Brashear
Why LB Pharmaceuticals Inc’s (LBRX) Stock Is Up 5.78%
As of Monday, August 03, LB Pharmaceuticals Inc’s LBRX share price has surged by 5.78%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | LBRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,096.8 | $476.9 | 47% |
|
| Shares Out (Mil) | 30.1 | 42.8 | 37% |
|
| Institutional Ownership | 99.1% | 81.8% | 85% |
|
| Float (Mil) | 26.5 | 44.5 | 33% |
|
| Beta | na | 0.71 | na |
|
| Avg Daily Volume (000s) | 421 | 362 | 55% |
|
| Price Change (52-week) |
111.6% | 54.5% | 95% |
|
| Growth | LBRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | na | (2.0%) | na |
|
| EPS (5yr) | na | 15.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 9 | 9 | |
| Current EPS | ($1.520) | ($5.474) | ($5.132) | |
| Month Ago EPS | ($1.564) | ($5.542) | ($5.036) | |
| # Rev Up | 2 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.930) | ($3.452) | ($4.408) | |
| Year/Year Chg | (11.2%) | 74.7% | 69.8% | |
| Financials | LBRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $416 | na |
|
| Net Income (TTM) (Mil) | ($86) | ($11) | 12% |
|
| EPS (TTM) | ($3.814) | ($0.700) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($82) | ($7) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $269 | $5 | 86% |
|
| Long-Term Debt (Q1) (Mil) | $4 | $6 | 24% |
|
| Enterprise Value (Q1) (Mil) | $1,233 | $494 | 43% |
|
| Valuation | LBRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.93 | 2.17 | 67% |
|
| P/E | na | 17.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | LBRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 3.2% | na |
|
| ROA | (45.0%) | (22.2%) | 13% |
|
| ROE | (75.0%) | (21.4%) | 12% |
|
| Liabilities to Assets | 8.1% | 32.8% | 5% |
|
| F-Score | 2 | 3 | 7% |
|
LB Pharmaceuticals Inc did not pass any screens on 10/14/2026.
